Colorectal cancer (CRC) is the second most commonly diagnosed cancer in China. Early detection and diagnosis of CRC are essential for improving survival rates. However, socioeconomic factors such as regional disparities, economic conditions, and varying levels of awareness impact the uptake of screening programs. Recently, rapid advancements in non-invasive tests, including high-quality fecal immunochemical tests and the emergence of stool and blood biomarkers for CRC, have facilitated improvements in early detection and diagnosis. Additionally, image-enhanced endoscopy, a group of advanced imaging technologies, has been developed to assist in the early identification of colorectal lesions, including narrow band imaging and linked-color imaging. The emergence of artificial intelligence also offers promising opportunities to improve early diagnosis and treatment of CRC. This review mainly introduces screening technologies and the current status of CRC screening in China, provides an overview of CRC early detection and diagnosis, and discusses the limitations and future prospects.

Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a novel series of orally available covalent CDK12/13 dual inhibitors, as a potential option against refractory and treatment-resistant cancers. Published in the Journal of Medicinal Chemistry (IF=7.2), the study showcases the discovery of compound 12b, a potent, selective, and safe therapy targeting CDK12/13, empowered by Insilico’s proprietary generative AI platforms including PandaOmics and Chemistry42.

Researchers used an innovative approach and analyzed data from a large sample involving residents of four state capitals in different regions of Brazil; study contributes to preventive strategies for this type of tumor.

Scientists at Lawson Research Institute (Lawson) of St. Joseph’s Health Care London and London Health Sciences Centre Research Institute (LHSCRI) are the first in the world to study fecal transplants using capsules containing microbes from the gut of healthy volunteers to improve the response of patients with advanced pancreatic cancer to chemotherapy. 

Drawing inspiration from the tardigrade, researchers developed a new strategy that may protect cancer patients from the side effects of radiation therapy.

 

A pioneering study has revealed new insights into the role of gastric bacteria in stomach cancer development that could pave the way for a more effective treatment of pre-cancer according to a study published today in Helicobacter.

Colorectal cancer, the second most common cause of cancer-related death, affects almost 2 million people worldwide every year. It is mainly treated with chemotherapy, but its effectiveness decreases over time due to the progressive resistance of tumor cells. A team from the University of Geneva (UNIGE) has identified specific alterations in certain lipids in cancer cells resistant to chemotherapy. These lipid signatures could serve as prognostic markers for understanding resistance to treatment and pave the way for personalized, targeted strategies to restore drug sensitivity. This work is published in the International Journal of Molecular Sciences.